In April 2021, we screened the CPGs developed by the Chinese Society of Cardiology and the American College of Cardiology/American Heart Association. We identified four routine therapies:
Reperfusion, including primary percutaneous coronary intervention (PCI) and fibrinolytic therapy. Fibrinolytic therapy could be performed by tenecteplase, reteplase, alteplase, streptokinase, urokinase, or prourokinase. RCTs evaluating delayed PCI or fibrinolytic therapy were excluded.
P2Y12 receptor inhibitors, including clopidogrel, ticagrelor, and prasugrel. RCTs evaluating loading P2Y12 receptor inhibitors administered before PCI or fibrinolytic therapy were excluded.
Statins, including atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and pitavastatin. We excluded RCTs evaluating loading statin therapy administered before PCI or fibrinolytic therapy.
Anticoagulants, including unfractionated heparin, enoxaparin, fondaparinux, and bivalirudin. We only included RCTs evaluating anticoagulants administered with fibrinolytic therapy.
